Health Blueprint

Back to Longevity News

News summary

StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation

Source: BioSpace - Funding • Published: 29 Oct 2026, 13:11

Summarized by Masters of Longevity from BioSpace - Funding.

Company closed a $30 million Series A to advance a wrist-worn AF therapy.

StimCardio Closes Oversubscribed $30 Million Series A Financing to Advance Wearable Therapeutic for Atrial Fibrillation
Key Takeaways
  • Company raised $30 million to support a pivotal trial.
  • Rhyvive is a wrist-worn device delivering median nerve stimulation.
  • A randomized pilot showed reduced recurrent atrial arrhythmias.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.